The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection

The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in... Human leukocyte antigen (HLA) alleles are associated with both the progression of chronic hepatitis C (CHC) and the sustained virological response (SVR) to antiviral therapy. HLA-A*02 is the most common HLA allele in people of European/Caucasian descent and the Chinese and Japanese population. Therefore, we investigated whether HLA-A*02 expression is associated with disease outcome in Chinese CHC patients. Three hundred thirty-one treatment-naïve CHC patients were recruited in this study. The expression of HLA-A*02 was tested by FACS and LABType SSO assays. All patients were treated weekly with pegylated interferon plus ribavirin (PEG-IFN/RBV) according to a standard protocol. Virological response was assessed by TaqMan assay at the 4th, 12th, 24th, and 48th week of therapy, and again at the 24th week post-therapy. By the end of the study, 293 CHC patients, including 144 HLA-A*02-positive patients and 149 HLA-A*02-negative patients, were evaluable for analysis. There were no statistical differences in clinicopathological parameters between HLA-A*02-positive and negative patients before antiviral therapy ( P > 0.05). The HLA-A*02-positive patients had a higher rapid virological response (RVR, 74.3 % versus 62.4 %, P = 0.03) and SVR (78.5 % versus 64.4 %, P = 0.01) and a lower relapse rate (4.2 % versus 11.9 %, P = 0.03) than HLA-A*02-negative patients. Multivariable logistic regression analysis showed that HLA-A*02 expression, liver fibrosis stages <S3, HCV genotype 2a, IL-28B rs8099917 TT, and RVR were independent predictive factors of SVR ( P < 0.05). Host HLA-A*02 allele expression is associated with SVR, highlighting the importance of considering HLA-A*02 as a predictor of the response to PEG-IFN/RBV treatment in the Chinese population with CHC. Archives of Virology Springer Journals

The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection

Loading next page...
Springer Vienna
Copyright © 2015 by Springer-Verlag Wien
Biomedicine; Virology; Medical Microbiology; Infectious Diseases
Publisher site
See Article on Publisher Site


  • Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence
    Mohd Hanafiah, K; Groeger, J; Flaxman, AD; Wiersma, ST
  • The impact of hepatitis C burden: an evidence-based approach
    Younossi, ZM; Kanwal, F; Saab, S; Brown, KA; El-Serag, HB; Kim, WR; Ahmed, A; Kugelmas, M; Gordon, SC
  • Determinants of viral clearance and persistence during acute hepatitis C virus infection
    Thimme, R; Oldach, D; Chang, KM; Steiger, C; Ray, SC; Chisari, FV
  • Hepatitis C virus clearance correlates with HLA-DR expression on proliferating CD8+ T cells in immune-primed chimpanzees
    Zubkova, I; Duan, H; Wells, F; Mostowski, H; Chang, E; Pirollo, K; Krawczynski, K; Lanford, R; Major, M
  • Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source
    McKiernan, SM; Hagan, R; Curry, M; McDonald, GS; Kelly, A; Nolan, N; Walsh, A; Hegarty, J; Lawlor, E; Kelleher, D
  • Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans
    Harris, RA; Sugimoto, K; Kaplan, DE; Ikeda, F; Kamoun, M; Chang, KM
  • Host genetics of HIV acquisition and viral control
    Shea, PR; Shianna, KV; Carrington, M; Goldstein, DB
  • Quantitative and functional differences in CD8+ lymphocyte responses in resolved acute and chronic hepatitis C virus infection
    Lancaster, T; Sanders, E; Christie, JM; Brooks, C; Green, S; Rosenberg, WM
  • Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
    Thomas, DL; Thio, CL; Martin, MP; Qi, Y; Ge, D; O’Huigin, C; Kidd, J; Kidd, K; Khakoo, SI; Alexander, G; Goedert, JJ; Kirk, GD; Donfield, SM; Rosen, HR; Tobler, LH; Busch, MP; McHutchison, JG; Goldstein, DB; Carrington, M
  • The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending
    Pawlotsky, JM
  • Sticker shock and the price of new therapies for hepatitis C: is it worth it?
    Reau, NS; Jensen, DM
  • Chronic hepatitis C virus (HCV) disease burden and cost in the United States
    Razavi, H; Elkhoury, AC; Elbasha, E; Estes, C; Pasini, K; Poynard, T; Kumar, R
  • Treatment of chronic hepatitis C in Asia: when East meets West
    Yu, ML; Chuang, WL

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial